{"frequencyBands":{"HP:0040280":[100,100],"HP:0040281":[80,99],"HP:0040282":[30,79],"HP:0040283":[5,29],"HP:0040284":[1,4],"HP:0040285":[0,0]},"page":{"anchorSlug":"primary-hyperoxaluria-type-2","columns":[{"gene":"","key":"population-dde4994b75c26f2420e7","label":"Hyperoxaluria, primary, type II","mondoId":"MONDO:0009824","onsetQualifier":null,"originColumnKey":"MONDO:0009824/OMIM:260000","originalViews":[{"key":"MONDO:0009824/OMIM:260000","label":"Hyperoxaluria, primary, type II","scopeLabel":"OMIM:260000","sourceScope":"This column retains the native source entry. It is not a pooled estimate for the umbrella condition."}],"recordKeys":["14c7d60341fcd3b237dd42fa8acff7fa2c25d8765a3c86d55ba8ed3956cdc627","35329779388df02c62fd93ccde6d8cd366eb9189140e42030478210ad0ba7489","7e1f3a8efbfeaef9db68c9f9570a5c818e3738766a4a6963b808d10c745ad956","8588c6abdc6d9a5d1503f324fe639e12c50dfe098711ed398e1972a9368d0f18","a212c0feaaecf3a1631c09141cf7f4a79de329c18c2e4039ee89c6b29a014a64","ca3a44c692a4308ea72dd37dcbd5f3121832b3b2f315d0eed8a0d7fff603ce12","cc76bce07e8f7d102811d4ff4980740780f9ca445583276eb0c88dca7adeb092","dce52c7418f0f53e879fd7851505acc9457ab1135922b8e5be43eb23724d137c","ee06602c7310898f726a6afd383c586d61354f4ae79c6e972c191d1157c2ba1c","faebe6f207d9a2d24e38efc9b1e8d67c748bc487ee4de64f29335d9230007a8c"],"recordQualifiers":{},"scopeLabel":"OMIM:260000","sourceIds":["OMIM:260000"],"sourceScope":"This column retains the native source entry. It is not a pooled estimate for the umbrella condition."},{"gene":"","key":"population-e8281078e366cb1da620","label":"Primary hyperoxaluria type 2","mondoId":"MONDO:0009824","onsetQualifier":null,"originColumnKey":"MONDO:0009824/ORPHA:93599","originalViews":[{"key":"MONDO:0009824/ORPHA:93599","label":"Primary hyperoxaluria type 2","scopeLabel":"ORPHA:93599","sourceScope":"This column retains the native source entry. It is not a pooled estimate for the umbrella condition."}],"recordKeys":["24b1b9adcfec701633369c53c87cc095c45dcca4b584d1d6b988fa57e6f7a28f","281cd4371b404c065e02d838fd8c1cdbfe233881569d245f60e16e96c4c87db5","36e502131701ac03c697e7ea967427c94fcc85cdf437b2483078d234b40a7659","4dc1799ddaed70cf07affbd79d275f64371c6e5a725da98eed79e09530f229d6","691ef45684b11279cba06c63328ea169bfb7d849037b72c367069c4794ac7cf6","ec70aa00ffb6d048b043cc0e47169d079850287044b0a8dfd7a96b9ee05f3357"],"recordQualifiers":{},"scopeLabel":"ORPHA:93599","sourceIds":["ORPHA:93599"],"sourceScope":"This column retains the native source entry. It is not a pooled estimate for the umbrella condition."}],"comparison":{"collapseColumnsLabel":"Show default populations","defaultColumnKeys":["population-dde4994b75c26f2420e7","population-e8281078e366cb1da620"],"expandColumnsLabel":"Show all source populations","intro":"Features recorded for this MONDO node. Related-node evidence is available through separately scoped comparisons.","primaryFeatureIds":["HP:0012100","HP:0011280","HP:0008672","HP:6000670","HP:0000790","HP:0003159","HP:0000787"],"scopeNoteHtml":"<p>Each column retains its native condition identifier, assessed population and annotation references. Counts are not pooled.</p>"},"coverage":{"countRecords":7,"emptyColumnKeys":[],"hpoRelease":"2026-06-23","narrativeSourceChanges":[],"records":16,"sourceGroups":{"omim":1,"orphanet":6,"published":9}},"features":[{"hpoId":"HP:0012100","label":"Abnormal circulating creatinine concentration","primary":true},{"hpoId":"HP:0011280","label":"Abnormality of urine calcium concentration","primary":true},{"hpoId":"HP:0008672","label":"Calcium oxalate nephrolithiasis","primary":true},{"hpoId":"HP:6000670","label":"Elevated urinary L-glycerate level","primary":true},{"hpoId":"HP:0000790","label":"Hematuria","primary":true},{"hpoId":"HP:0003159","label":"Hyperoxaluria","primary":true},{"hpoId":"HP:0000787","label":"Kidney stone","primary":true},{"hpoId":"HP:0001942","label":"Metabolic acidosis","primary":false},{"hpoId":"HP:0000121","label":"Nephrocalcinosis","primary":false},{"hpoId":"HP:0000010","label":"Recurrent urinary tract infections","primary":false},{"hpoId":"HP:6000638","label":"Reduced hepatic glyoxylate reductase activity","primary":false},{"hpoId":"HP:0000083","label":"Renal insufficiency","primary":false},{"hpoId":"HP:0006000","label":"Ureteral obstruction","primary":false}],"ledeHtml":"Primary hyperoxaluria type 2 (PH2), caused by deficiency of the enzyme glyoxylate reductase/hydroxypyruvate reductase (GR/HPR), is characterized by recurrent nephrolithiasis (deposition of calcium oxalate in the renal pelvis / urinary tract), nephrocalcinosis (deposition of calcium oxalate in the renal parenchyma), and end-stage kidney disease (ESKD). After ESKD, oxalosis (widespread tissue deposition of calcium oxalate) usually develops. Symptom onset is typically in childhood.","mondoId":"MONDO:0009824","node":{"canonicalSlug":"primary-hyperoxaluria-type-2","comparisons":[{"documentSha256":"e0d61b441f613dc5c4be209ea02f815ea23c5e26f673dc1c0451d7efa28eaa8f","key":"legacy-primary-hyperoxaluria","kind":"legacy","label":"primary hyperoxaluria","memberIds":["MONDO:0002474","MONDO:0009824","MONDO:0013327"],"mondoId":"MONDO:0002474","url":"https://kcjyutqgtpgteszueluf.supabase.co/storage/v1/object/public/community-guides/learn-data/primary-hyperoxaluria.e0d61b441f613dc5c4be209ea02f815ea23c5e26f673dc1c0451d7efa28eaa8f.json"},{"documentSha256":"154b805a82b66671d7fe404fae2eef490c2a51bb1d56920205679a4096052bd3","key":"expanded-primary-hyperoxaluria","kind":"expanded","label":"primary hyperoxaluria","memberIds":["MONDO:0002474","MONDO:0009823","MONDO:0009824","MONDO:0013327"],"mondoId":"MONDO:0002474","url":"https://kcjyutqgtpgteszueluf.supabase.co/storage/v1/object/public/community-guides/learn-data/node-comparison-154b805a82b66671d7fe.154b805a82b66671d7fe404fae2eef490c2a51bb1d56920205679a4096052bd3.json"}],"contexts":[],"lifecycle":"active","narrative":{"causes":[],"contentForm":"summary","matchMethod":"automatic-preferred-title","name":"Primary Hyperoxaluria Type 2","paragraphs":["Primary hyperoxaluria type 2 (PH2), caused by deficiency of the enzyme glyoxylate reductase/hydroxypyruvate reductase (GR/HPR), is characterized by recurrent nephrolithiasis (deposition of calcium oxalate in the renal pelvis / urinary tract), nephrocalcinosis (deposition of calcium oxalate in the renal parenchyma), and end-stage kidney disease (ESKD). After ESKD, oxalosis (widespread tissue deposition of calcium oxalate) usually develops. Symptom onset is typically in childhood."],"reviewed":"2017-12-21","scope":"exact","source":"GeneReviews","sourceExcerpt":"Summary / Clinical characteristics","sourceRelease":"2026-10-18 12:11:26.171872+00","upstream":"GeneReviews clinical characteristics","url":"https://www.ncbi.nlm.nih.gov/books/NBK2692/"},"ownColumnKeys":["population-dde4994b75c26f2420e7","population-e8281078e366cb1da620"],"publication":"published","relationships":[{"kind":"parent","label":"primary hyperoxaluria","mondoId":"MONDO:0002474","slug":"primary-hyperoxaluria"}],"schemaVersion":1,"searchIndex":"/node-search/manifest.json","sourceHolds":{},"summaryHolds":[{"reason":"Name scope not exact or reviewed","source":"GARD","url":"https://rarediseases.info.nih.gov/diseases/2836"}],"translation":"published"},"records":[{"frequencyKind":"count","key":"14c7d60341fcd3b237dd42fa8acff7fa2c25d8765a3c86d55ba8ed3956cdc627","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:260000","disease_name":"Hyperoxaluria, primary, type II","evidence":"PCS","frequency_raw":"0/1","hpo_id":"HP:0011280","is_excluded":true,"label":"Abnormality of urine calcium concentration","onset_id":null,"reference":"PMID:28569194","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"range","key":"24b1b9adcfec701633369c53c87cc095c45dcca4b584d1d6b988fa57e6f7a28f","raw":{"aspect":"P","body_system":"genitourinary","disease_id":"ORPHA:93599","disease_name":"Primary hyperoxaluria type 2","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0006000","is_excluded":false,"label":"Ureteral obstruction","onset_id":null,"reference":"ORPHA:93599","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"281cd4371b404c065e02d838fd8c1cdbfe233881569d245f60e16e96c4c87db5","raw":{"aspect":"P","body_system":"genitourinary","disease_id":"ORPHA:93599","disease_name":"Primary hyperoxaluria type 2","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0000787","is_excluded":false,"label":"Kidney stone","onset_id":null,"reference":"ORPHA:93599","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"count","key":"35329779388df02c62fd93ccde6d8cd366eb9189140e42030478210ad0ba7489","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:260000","disease_name":"Hyperoxaluria, primary, type II","evidence":"PCS","frequency_raw":"0/1","hpo_id":"HP:0012100","is_excluded":true,"label":"Abnormal circulating creatinine concentration","onset_id":null,"reference":"PMID:28569194","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"range","key":"36e502131701ac03c697e7ea967427c94fcc85cdf437b2483078d234b40a7659","raw":{"aspect":"P","body_system":"genitourinary","disease_id":"ORPHA:93599","disease_name":"Primary hyperoxaluria type 2","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0000121","is_excluded":false,"label":"Nephrocalcinosis","onset_id":null,"reference":"ORPHA:93599","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"4dc1799ddaed70cf07affbd79d275f64371c6e5a725da98eed79e09530f229d6","raw":{"aspect":"P","body_system":"metabolic","disease_id":"ORPHA:93599","disease_name":"Primary hyperoxaluria type 2","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0003159","is_excluded":false,"label":"Hyperoxaluria","onset_id":null,"reference":"ORPHA:93599","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"691ef45684b11279cba06c63328ea169bfb7d849037b72c367069c4794ac7cf6","raw":{"aspect":"P","body_system":"genitourinary","disease_id":"ORPHA:93599","disease_name":"Primary hyperoxaluria type 2","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0000010","is_excluded":false,"label":"Recurrent urinary tract infections","onset_id":null,"reference":"ORPHA:93599","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"count","key":"7e1f3a8efbfeaef9db68c9f9570a5c818e3738766a4a6963b808d10c745ad956","raw":{"aspect":"P","body_system":"genitourinary","disease_id":"OMIM:260000","disease_name":"Hyperoxaluria, primary, type II","evidence":"PCS","frequency_raw":"3/5","hpo_id":"HP:0008672","is_excluded":false,"label":"Calcium oxalate nephrolithiasis","onset_id":null,"reference":"PMID:28569194;PMID:10484776","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"8588c6abdc6d9a5d1503f324fe639e12c50dfe098711ed398e1972a9368d0f18","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:260000","disease_name":"Hyperoxaluria, primary, type II","evidence":"PCS","frequency_raw":"0/1","hpo_id":"HP:0001942","is_excluded":true,"label":"Metabolic acidosis","onset_id":null,"reference":"PMID:28569194","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"a212c0feaaecf3a1631c09141cf7f4a79de329c18c2e4039ee89c6b29a014a64","raw":{"aspect":"P","body_system":"genitourinary","disease_id":"OMIM:260000","disease_name":"Hyperoxaluria, primary, type II","evidence":"PCS","frequency_raw":"1/4","hpo_id":"HP:0000083","is_excluded":false,"label":"Renal insufficiency","onset_id":null,"reference":"PMID:10484776","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"ca3a44c692a4308ea72dd37dcbd5f3121832b3b2f315d0eed8a0d7fff603ce12","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:260000","disease_name":"Hyperoxaluria, primary, type II","evidence":"PCS","frequency_raw":"1/1","hpo_id":"HP:6000670","is_excluded":false,"label":"Elevated urinary L-glycerate level","onset_id":null,"reference":"PMID:28569194","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"reported","key":"cc76bce07e8f7d102811d4ff4980740780f9ca445583276eb0c88dca7adeb092","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:260000","disease_name":"Hyperoxaluria, primary, type II","evidence":"PCS","frequency_raw":null,"hpo_id":"HP:6000638","is_excluded":false,"label":"Reduced hepatic glyoxylate reductase activity","onset_id":null,"reference":"PMID:10484776","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"dce52c7418f0f53e879fd7851505acc9457ab1135922b8e5be43eb23724d137c","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:260000","disease_name":"Hyperoxaluria, primary, type II","evidence":"PCS","frequency_raw":"5/5","hpo_id":"HP:0003159","is_excluded":false,"label":"Hyperoxaluria","onset_id":null,"reference":"PMID:28569194;PMID:10484776","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"range","key":"ec70aa00ffb6d048b043cc0e47169d079850287044b0a8dfd7a96b9ee05f3357","raw":{"aspect":"P","body_system":"genitourinary","disease_id":"ORPHA:93599","disease_name":"Primary hyperoxaluria type 2","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0000083","is_excluded":false,"label":"Renal insufficiency","onset_id":null,"reference":"ORPHA:93599","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"reported","key":"ee06602c7310898f726a6afd383c586d61354f4ae79c6e972c191d1157c2ba1c","raw":{"aspect":"P","body_system":"genitourinary","disease_id":"OMIM:260000","disease_name":"Hyperoxaluria, primary, type II","evidence":"PCS","frequency_raw":null,"hpo_id":"HP:0000121","is_excluded":false,"label":"Nephrocalcinosis","onset_id":null,"reference":"PMID:10484776","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"reported","key":"faebe6f207d9a2d24e38efc9b1e8d67c748bc487ee4de64f29335d9230007a8c","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:260000","disease_name":"Hyperoxaluria, primary, type II","evidence":"TAS","frequency_raw":null,"hpo_id":"HP:0000790","is_excluded":false,"label":"Hematuria","onset_id":null,"reference":"OMIM:260000","source_release":"2026-06-23"},"sourceGroups":["omim"]}],"referenceLabels":{},"references":{"causeHtml":"<p class=\"section-source\">Source: <a href=\"https://www.ncbi.nlm.nih.gov/books/NBK2692/\" rel=\"noreferrer\">GeneReviews</a></p><p class=\"section-source\">Source: <a href=\"https://monarchinitiative.org/MONDO:0009824\" rel=\"noreferrer\">MONDO</a></p><details class=\"deep-dive\"><summary>Narrative source and scope</summary><dl><dt>Content</dt><dd>summary</dd><dt>Scope</dt><dd>exact</dd><dt>Match method</dt><dd>automatic-preferred-title</dd><dt>Upstream attribution</dt><dd>GeneReviews clinical characteristics</dd></dl></details>","identityNote":"MONDO identifies this node. Native source populations, annotation references and qualified comparison views retain their original scopes.","importantHtml":""},"sections":[{"bodyHtml":"<p>Primary hyperoxaluria type 2 (PH2), caused by deficiency of the enzyme glyoxylate reductase/hydroxypyruvate reductase (GR/HPR), is characterized by recurrent nephrolithiasis (deposition of calcium oxalate in the renal pelvis / urinary tract), nephrocalcinosis (deposition of calcium oxalate in the renal parenchyma), and end-stage kidney disease (ESKD). After ESKD, oxalosis (widespread tissue deposition of calcium oxalate) usually develops. Symptom onset is typically in childhood.</p><p class=\"section-source\">Source: <a href=\"https://www.ncbi.nlm.nih.gov/books/NBK2692/\" rel=\"noreferrer\">GeneReviews</a></p>","key":"overview","title":"Overview"}],"sharedSources":[],"slug":"primary-hyperoxaluria-type-2","sourceDocuments":[{"name":"GeneReviews: Primary Hyperoxaluria Type 2","reviewed":"2017-12-21","source_release":"2026-10-18 12:11:26.171872+00","url":"https://www.ncbi.nlm.nih.gov/books/NBK2692/"},{"name":"MONDO: primary hyperoxaluria type 2","reviewed":null,"source_release":"releases/2026-10-06","url":"https://monarchinitiative.org/MONDO:0009824"}],"sourceNote":"","synonyms":["D-glycerate dehydrogenase deficiency","GRHPR primary hyperoxaluria","HP2","hyperoxaluria, primary, type II","L-glyceric aciduria","primary hyperoxaluria caused by mutation in GRHPR","primary hyperoxaluria type 2","primary hyperoxaluria type II"],"takeawayHtml":"","title":"primary hyperoxaluria type 2"},"schemaVersion":1}
